ArticleJournal of the National Cancer Institute2015
Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women.
Open access · bronzeAbstract read
In one paragraph
Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Early menarche and breast cancer risk: a systematic review and meta-analysis of 74 case-control studies.Cancer causes & control : CCC · 2026Pooled it
- The unique risk factor profile of triple-negative breast cancer: a comprehensive meta-analysis.Journal of the National Cancer Institute · 2024Pooled it
- Nutritional Formulation for Patients with Angelman Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study of Exogenous Ketones.The Journal of nutrition · 2021Trial
- Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study.PloS one · 2017Trial
- Association between cumulative lifetime exposure to reproductive hormones and tumor-infiltrating lymphocytes, CD4 +, and CD8 + T cells among women with breast cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Natural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis.British journal of cancer · 2026Article
- Associations of lifetime cumulative estrogen exposure with lifecourse social exposures, cognitive decline, and dementia risk among postmenopausal White, Black, and Latina women.The journals of gerontology. Series B, Psychological sciences and social sciences · 2026Article
- Manganese-induced Precocious Puberty Alters Mammary Epithelial Cell Proliferation in Female Rats.Endocrinology · 2025Article
- Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.Breast cancer research : BCR · 2024Article
- The prognostic significance of human ovarian aging-related signature in breast cancer after surgery: A multicohort study.Frontiers in immunology · 2023Article
- Annual report to the nation on the status of cancer, part 1: National cancer statistics.Cancer · 2022Article
- Gestational diabetes and risk of breast cancer before age 55 years.International journal of epidemiology · 2022Article
- Racial and regional disparities of triple negative breast cancer incidence rates in the United States: An analysis of 2011-2019 NPCR and SEER incidence data.Frontiers in public health · 2022Article
- Dietary Vitamin A and Breast Cancer Risk in Black Women: The African American Breast Cancer Epidemiology and Risk (AMBER) Consortium.The Journal of nutrition · 2021Article
- Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya.Breast cancer research : BCR · 2021Article
- Reproductive factors and risk of breast cancer in black South African women.Cancer causes & control : CCC · 2021Article
- Epidemiology of Basal-like and Luminal Breast Cancers among Black Women in the AMBER Consortium.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Relationships between Breast Feeding and Breast Cancer Subtypes: Lessons Learned from Studies in Humans and in Mice.Cancer research · 2020Review
- Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities study.International journal of cancer · 2020Article
- Reproductive factors and risk of breast cancer by tumor subtypes among Ghanaian women: A population-based case-control study.International journal of cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 1 country.
Christine B AmbrosoneRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK). christine.ambrosone@roswellpark.org.
Gary ZirpoliRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Chi-Chen HongRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Song YaoRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Melissa A TroesterRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Elisa V BanderaRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Pepper SchedinRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Traci N BetheaRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Virginia BorgesRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Song-Yi ParkRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Dhyan ChandraRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Lynn RosenbergRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Laurence N KolonelRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Andrew F OlshanRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Julie R PalmerRoswell Park Cancer Institute, Buffalo, NY (CBA, GZ, CCH, SY, DC); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Oregon Health & Science University, Portland, OR (PS); Slone Epidemiology Center at Boston University, Boston, MA (TNB, LR, JRP); University of Colorado Denver School of Medicine, Denver, CO (VB); University of Hawaii Cancer Center, Honolulu, HI (SYP, LNK).
Boston University · USRoswell Park Comprehensive Cancer Center · USRutgers Cancer Institute of New JerseyUniversity of Colorado Denver · USUniversity of North Carolina at Chapel Hill · USRutgers, The State University of New Jersey · USUNC Lineberger Comprehensive Cancer Center
Funding
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KATHERINE A. HOADLEY · 1992 to 2026
$59.3MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3MFOLLOW-UP STUDY FOR CAUSES OF ILLNESS IN BLACK WOMENR01CA058420 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 1999 to 2013
$20.7MReproduction, Lactation and Hormonal Factors in Breast Cancer SubtypesP01CA151135 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B., OLSHAN, ANDREW · 2011 to 2017
$18.1MA Follow-up Study for Causes of Cancer in Black WomenUM1CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROSENBERG, LYNN · 2012 to 2017
$13.7MUnderstanding Ethnic Differences in Cancer: The Multiethnic Cohort StudyUM1CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HENDERSON, BRIAN E, LE MARCHAND, LOIC · 2012 to 2014
$11.3MObesity, related comorbidities, and breast cancer outcomes in African AmericansR01CA185623 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI BANDERA, ELISA V, DEMISSIE, KITAW · 2014 to 2018
$6.2MNSAIDs During Postpartum Involution for Breast Cancer ChemopreventionR01CA169175 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHEDIN, PEPPER J · 2013 to 2024
$4.8MRace &Risk Factors for Early/Aggressive Breast CancerR01CA100598 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B. · 2004 to 2008
$4.8MMULTIETHNIC/MINORITY COHORT STUDY OF DIET AND CANCERR01CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 1993 to 2002
$4.5MNCI NIH HHS P01 CA151135NCI NIH HHS P50 CA058223NCI NIH HHS P50 CA58223NCI NIH HHS R01 CA058420NCI NIH HHS R01 CA100598NCI NIH HHS R01 CA169175NCI NIH HHS R01 CA185623NCI NIH HHS R01 CA54281NCI NIH HHS UM1 CA164973NCI NIH HHS UM1 CA164974NIEHS NIH HHS P30 ES010126PHS HHS U01 ESO19472
Abstract
backgroundMenarche is a critical time point for diverging fates of mammary cells of origin. African American women have young age at menarche, which could be associated with their high rates of estrogen receptor-negative (ER-) breast cancer.
methodsIn the AMBER Consortium, using harmonized data from 4426 African American women with breast cancer and 17 474 controls, we used polytomous logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for ages at menarche and first live birth (FLB), and the interval between, in relation to ER+ and ER- breast cancer. All statistical tests were two-sided.
resultsRisk of ER- breast cancer was reduced with later age at menarche among both parous and nulliparous women (≥15 vs <11 years OR = 0.62, 95% CI = 0.48 to 0.81 and OR = 0.56, 95% CI = 0.29 to 1.10, respectively), with no effect of age at FLB. For ER+ breast cancer, the inverse association was weaker among nulliparous women. While longer intervals between menarche and FLB were associated with increased risk of ER+ breast cancer in a dose-response fashion (OR for 20 year interval = 1.39, 95% CI = 1.08 to 1.79, P trend = .003), ER- risk was only increased for intervals up to 14 years and not beyond (P trend = .33).
conclusionsWhile ER- breast cancer risk was markedly reduced in women with a late age at menarche, there was not a clear pattern of increased risk with longer interval between menarche and FLB, as was observed for ER+ breast cancer. These findings indicate that etiologic pathways involving adolescence and pregnancy may differ for ER- and ER+ breast cancer.
Indexed as
MenarcheReproductive HistoryAdolescentAdultAgedAge FactorsBlack or African AmericanBreast FeedingBreast NeoplasmsChildConfounding Factors, EpidemiologicFemaleHumansLogistic ModelsMenopauseMiddle AgedReceptors, Estrogen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.